We have conducted a retrospective exploration of the safety and anti-tumor activity of PD-1 antibody monotherapy, as well as its combination with other regimens, in pediatric cancer patients of Asian descent,14 supporting the practical foundations for PD-1 inhibitors for advanced pediatric cancers in a prospective study. Here, PDCD1 is linked to cancer.